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Atherogenic lipid stress induces platelet hyperactivity through CD36-mediated hyposensitivity to 
prostacyclin – the role of phosphodiesterase 3A.  
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ABSTRACT  
Prostacyclin (PGI
2
) controls platelet activation and thrombosis through a cyclic adenosine monophosphate 
(cAMP) signalling cascade. However, in patients with cardiovascular diseases this protective mechanism fails for 
reasons that are unclear. Using both pharmacological and genetic approaches we describe a mechanism by 
which oxidised low density lipoproteins (oxLDL) associated with dyslipidaemia promote platelet activation 
through impaired PGI
2 
sensitivity and diminished cAMP signalling. In functional assays using human platelets, 
oxLDL modulated the inhibitory effects of PGI
2
, but not a phosphodiesterase (PDE)-insensitive cAMP analogue, 
on platelet aggregation, granule secretion and in vitro thrombosis. Examination of the mechanism revealed that 
oxLDL promoted the hydrolysis of cAMP through the phosphorylation and activation of PDE3A, leading to 
diminished cAMP signalling. PDE3A activation by oxLDL required Src family kinases, Syk and protein kinase C. 
The effects of oxLDL on platelet function and cAMP signalling were blocked by pharmacological inhibition of 
CD36, mimicked by CD36-specific oxidised phospholipids and ablated in CD36
-/-
 murine platelets. The injection 
of oxLDL into wild type mice strongly promoted FeCl
3
 induced carotid thrombosis in vivo, which was prevented 
by pharmacological inhibition of PDE3A. Furthermore, blood from dyslipidaemic mice was associated with 
increased oxidative lipid stress, reduced platelet sensitivity to PGI
2 
ex vivo
 
and diminished PKA signalling. In 
contrast, platelet sensitivity to a PDE-resistant cAMP analogue remained normal. Genetic deletion of CD36, 
protected dyslipidaemic animals from PGI
2 
hyposensitivity
 
and restored
 
PKA signalling.  These data suggest 
that CD36 can translate atherogenic lipid stress into platelet hyperactivity through modulation of inhibitory 
cAMP signalling. 
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INTRODUCTION  
Myocardial infarction (MI) is characterised by platelet-driven atherothrombotic events that lead to acute 
occlusion of a coronary vessel. Excessive platelet activation is controlled by endothelial derived nitric oxide (NO) 
and prostacyclin (PGI
2
)
1
, but action of these protective agents are overcome in MI by mechanisms that are yet 
to be elucidated. A key risk factor for MI is dyslipidaemia, which is strongly associated with a pro-thrombotic 
phenotype linked to atherothrombosis and platelet hyperactivity
2,3
. The blood of high-risk individuals with 
dyslipidemia is characterized by increased plasma lipid peroxides, with low density lipoproteins (LDL) serving as 
a highly abundant carriers for these oxidatively-modified lipids
4–6
. Oxidised LDL (oxLDL) are circulating 
pathological ligands that can enhance thrombosis through their ability to promote platelet hyperactivity. In 
vitro experimentation demonstrates that these modified lipoproteins can cause direct activation of platelets 
and also potentiate platelet activation induced by physiological agonists such as thrombin, ADP and 
epinephrine
7–10
. However, the potential pathophysiological importance of these observations for thrombosis in 
vivo remain unclear. 
The scavenger receptor CD36 has emerged as a potential conduit for transducing plasma lipid stress into 
platelet hyperactivity and thrombosis, through the recognition of lipoprotein associated molecular patterns 
(LAMPs). CD36, alone or potentially in combination with Toll-Like Receptor (TLR)2 and TLR6 drive a complex 
series of intracellular signaling events that are associated with platelet activation
11–15
. Upon ligation of CD36, 
Src family kinases constitutively associated with the receptor, drive the activation of Syk, Vav-1, PLCγ2, ERK5 
and JNK that are associated with platelet activation
13,16–18
 More recently, data has emerged to suggest that the 
signalling events promote the generation of reactive oxygen species (ROS)
14,16,17
. ROS in turn activate ERK to 
drive thrombosis directly by platelet hyperactivity and caspase-dependent procoagulant activity
18,19
. Moreover, 
we found that ROS diminish sensitivity to the nitric oxide (NO)-stimulated cGMP-PKG inhibitory signaling 
cascade to reduce the threshold for platelet activation
17
. These data suggest that the translation of atherogenic 
lipid stress by platelet CD36 is functionally linked to both stimulation of activatory signalling pathways and to 
an as of yet ill-defined modulation of inhibitory pathways.  
PGI
2
 is the most potent endogenous regulator of platelet function with both genetic and pharmacological 
modulation of the pathway linked to accelerated thrombosis in vivo
20
. PGI
2
 activates a cyclic adenosine 
monophosphate (cAMP) signalling pathway that leads to subsequent activation of protein kinase A (PKA) in 
platelets and results in the phosphorylation of numerous proteins
21
, 
linked to the inhibition of Ca
2+
 mobilisation, 
dense granule secretion, spreading, integrin α
IIb
β
3
 activation and aggregation in vitro
20
. To ensure optimal 
platelet function, cAMP levels are tightly regulated by the hydrolysing enzymes phosphodiesterase (PDE)2A 
and 3A. The pharmacological inhibition or genetic ablation of PDE3A in murine and human platelets reduces 
thrombotic potential
22,23
. Thus, factors that alter platelet inhibition by influencing cAMP synthesis or hydrolysis 
may be critical modulators of atherothrombosis and potentially lead to a pro-thrombotic phenotype. Given the 
established link between oxidised lipid stress and excessive platelet activation, the aim of this study was to 
determine if oxidatively modified lipoproteins could promote platelet hyperactivity through modulation of the 
PGI
2
/cAMP signalling pathway. 
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METHODS 
 
Reagents 
Phospho-PKA Substrate (RRXS*/T*) Rabbit mAb and phospho-VASP-Ser
157/239
 antibodies were from Cell 
Signaling Technology (Danvers, USA). PDE3A antibodies were from the MRC Unit (Dundee University, 
Scotland). Anti-β-Tubulin antibody was from Millipore (Nottingham, UK). BD Phosflow Lyse/Fix Buffer was 
from BD Biosciences (Oxford, UK). OxPC-E06 mAb was from Avanti Polar Lipids (Alabaster, USA). FITC-labeled 
Rat Anti-Mouse P-selectin (CD62P) and PE-labeled JON/A antibodies were from Emfret Analytics (Würzburg, 
Germany). Alexa-Fluor647 Goat anti-Rabbit IgG, Alexa-Fluor488 Succinimidyl Ester and Pacific-Blue 
Succinimidyl Ester were from ThermoFisher Scientific (Waltham, USA). PAR-1 peptide was from Anaspec 
(Fremont, USA). Anti-CD36 Antibody (FA6-152) was from Abcam (Cambridge, UK). Phosphodiesterase Activity 
Assay Kit was from Enzo Life Sciences (Exeter, UK). cAMP Biotrack EIA was from GE Healthcare 
(Buckinghamshire, UK). Horm Collagen was from Nycomed (Munich, Germany). PGI
2
 and Cholesterol Assay Kit 
were from Cayman Chemical (Cambridge, UK). Vena8 Endothelial+ biochips were from Cellix (Hertfordshire, 
UK). All other reagents were from Sigma-Aldrich (Dorset, UK). 
 
Experimental animals 
CD36
-/-
 mice were provided by Prof. Maria Febbraio (University of Alberta, Canada). C57BL/6 were from Charles 
River (Kent, UK). For high-fat diet studies, male mice were fed a 45% Western diet (Special Diet Services) for 
12–16 weeks.  Sex/age-matched littermates were fed a normal chow for the duration of the experiments and 
used as controls. For all remaining experiments male C57BL/6 and CD36
-/-
 were used at 8 weeks of age.  
 
Isolation and oxidation of plasma LDL 
LDL (density 1.019–1.063 g/ml) was prepared from fresh human plasma by sequential density 
ultracentrifugation and oxidised with CuSO
4
 (10 µmol/L)
14
. Separate preparations of LDL were used to repeat 
the individual experiments. 
 
Platelet aggregation, flow assays, flow cytometric analysis, intravital microscopy, immunoprecipitation, 
immunoblotting, PDE activity assay and cAMP measurement. 
Detailed methods are presented in the Supplemental methods.  
 
Statistical analysis 
Experimental data was analysed by Graphpad Prism 6 (La Jolla, USA). Data are presented as means±standard 
error of the mean (SEM) of at least 3 different experiments. Differences between groups were calculated using 
Mann-Whitney U Test or Kruskal-Wallis Test for non-parametric testing and statistical significance accepted at 
p≤0.05.  
 
All studies were approved by the Hull York Medical school Ethics committee and University of Leeds Research 
Ethics committee.    
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RESULTS 
Oxidised LDL causes platelet hyposensitivity to PGI
2
. 
Treatment of human washed platelets with PGI
2
 (20 nM) for 1 minute, at a timepoint that induces maximal 
cAMP mediated signalling
24
 reduced thrombin (0.05 U/ml)-induced aggregation from 89.0±4.1 to 9.4±4.4% 
(p<0.01) (Figure 1A). Next, platelets were treated with oxLDL or control native LDL (nLDL) (50 µg/ml) for 2 
minutes prior to the addition of PGI
2 
(20 nM)
 
and thrombin (0.05 U/ml). The presence of oxLDL caused a partial 
recovery in thrombin-stimulated platelet aggregation to 50.0±9.3 (p<0.015 versus control), without stimulating 
aggregation directly (Figure 1A). In contrast, PGI
2
-mediated inhibition was unaffected by nLDL (5.8±1.2%). 
Similar data was obtained when platelets were stimulated with collagen (Suppl. Figure 1). Next the effects of 
oxLDL in whole blood were examined. Stimulation of whole blood with PAR-1 peptide (10 µM) increased P-
selectin expression, which was reduced by pre-treatment with PGI
2
 (20 nM). Consistent with the aggregation 
experiments, oxLDL reduced inhibitory effects of PGI
2
 (Figure 1B). Finally, the effects of oxLDL under 
physiological conditions of arterial flow were examined. Perfusion of whole blood over collagen coated biochips 
led to platelet deposition and thrombus formation (Figure 1Ci and ii), with surface coverage inhibited by PGI
2
 
(20nM) from 14.9±2.9 to 3.8±1.7% (p<0.05). OxLDL, but not nLDL, prevented PGI
2
-mediated inhibition of 
platelet deposition (8.1±1.9%; p<0.05 compared to PGI
2
 alone). OxLDL alone caused a small, but non-significant 
increase in thrombosis and was incorporated into the thrombi as evidenced by staining for oxidised lipid 
epitopes (Figure 1D). These data demonstrate that under a variety of different conditions oxLDL reduces 
platelet sensitivity to PGI
2
. 
 
Oxidised LDL modulates cAMP signalling through increased PDE3A activity. 
PGI
2
 inhibits platelets through the stimulation of cAMP-PKA signalling cascade.
20
 Given the reduced platelet 
sensitivity to PGI
2
, the direct effect of oxLDL on platelet cAMP metabolism were tested. Incubation with PGI
2
 
caused a significant increase in platelet cAMP concentrations (1814±166 fmol cAMP/1x10
8
 platelets; p<0.05 
versus basal). When platelets were treated with nLDL (50 µg/ml), the ability of the prostanoid to elevate cAMP 
was unaffected (1885±203 fmol cAMP/1x10
8
 platelets), while oxLDL (50 µg/ml) prevented PGI
2
-induced 
accumulation of cAMP (481±23 fmol cAMP/1x10
8
 platelets; p<0.05 compared to PGI
2
 alone) and also reduced 
basal cAMP concentrations (not significant) (Figure 2Ai). To determine if oxLDL blocked cAMP synthesis or 
accelerated cAMP breakdown by phosphodiesterase 3A (PDE3A) and PDE2
25
,
25
 the PDE2A inhibitor EHNA (20 
µM) and the PDE3A inhibitor milrinone (10 µM) were used. Consistent with previous studies, both inhibitors 
potentiated cAMP accumulation in response to PGI
2
.
28
  
26
 
OxLDL reduced cAMP levels in the presence of EHNA 
(2645±122 to 488±7623 fmol cAMP/1x10
8
 platelets, p<0.05), but failed to prevent cAMP accumulation in the 
presence of milrinone (4761±170 to 4386±15723 fmol cAMP/1x10
8
 platelets p<0.05 ) (Figure 2Aii and 2Aiii). To 
confirm that the reduction in cAMP accumulation was not restricted to PGI
2, 
platelets were stimulated with 
forskolin, which increases cAMP in a receptor-independent non-compartmentalised mechanism. Forskolin (10 
µM)-stimulated elevation in cAMP was prevented by preincubation with oxLDL (9506±526 to 4506±1136 fmol 
cAMP/2x10
8
 platelets; p < 0.05) (Figure 2B).   
Next, the effects of oxLDL on cAMP signalling were assessed. PGI
2
 (50 nM) induced robust phosphorylation of a 
number of PKA substrates with apparent molecular weights of; 150, 100, 75, 70, 50, 37 and 20kDa (Figure 2C 
upper panel), and specifically vasodilator-stimulated phosphoprotein (VASP) (phosphoVASP-ser
157
)
 
(Figure 2C 
middle panel) an established target of PKA signalling
27
.
  
These phosphorylation events were diminished by 
oxLDL (50 μg/ml), but unaffected by nLDL (50 μg/ml) (Figure 2Cii). To further establish that the reduced 
signalling response was due to enhanced cAMP hydrolysis, the experiment was repeated with 8-CPT-6-Phe-
cAMP (50µM), a cell permeable non-hydrolysable (PDE resistant) analogue of cAMP (Suppl. Figure 2). Using a 
concentration that produced an equivalent quantity of intracellular cAMP (Suppl. Figure 3) as PGI
2
 (50 nM), 8-
 6
CPT-6-Phe-cAMP caused robust phosphorylation of PKA substrates, which were unaffected by oxLDL (Figure 
2D). These data suggest that oxLDL may regulate platelet sensitivity to PGI
2
 through modulation of the cAMP-
signalling cascade by PDE3A.   
 
CD36 is required for oxLDL modulation of cAMP signalling. 
Previously, we and others, have shown that CD36 transduces the effects of oxLDL into platelet 
hyperactivity
14,18,28,29
. To examine the role of CD36 in linking oxLDL to altered cAMP signalling we used a three-
pronged strategy; (i) the CD36 blocking antibody FA6-152, (ii) the oxidised phospholipid oxPC
CD36
, a CD36-
specific pathological ligand present in oxLDL,
26
 and (iii) murine platelets deficient in CD36 (Suppl. Figure 4). This 
strategy, particularly the use of oxPC
CD36
, previously to account for differences in human and murine platelet 
sensitivity to human oxLDL. PGI
2
 induced a robust phosphorylation of both the preferred ser
157
 site and 
alternative PKA phosphorylation site ser
239
 in human platelets
30
, which was reduced significantly by oxLDL. The 
presence of FA6-152 (1 μg/ml), but not control IgG (1 μg/ml), caused a significant recovery in phosphoVASP-
ser
157
 (Figure 3A and B). OxPC
CD36
 (25 µM), 
 
but not the control lipid, PAPC (25 µM), diminished phospoVASP-
ser
157 
in response to PGI
2 
(Figure 3C). Thrombin-induced aggregation of platelets isolated from WT and CD36
-/-
 
mice was indistinguishable and PGI
2
 (20 nM) caused complete inhibition of aggregation with only shape change 
remaining (Figure 3D and E). However, in CD36-deficient platelets oxPC
CD36
 (25 µM) did not influence the 
inhibitory effects of PGI
2
 (Figure 3E). To confirm the mechanism underpinning these observations we examined 
cAMP signalling. PGI
2
 (20 nM) caused a significant increase in cAMP in both WT and CD36
-/-
 platelets (4382±175 
and 4128±366 fmol cAMP/1x10
8
 platelets). Preincubation with oxLDL, but not nLDL, reduced cAMP 
accumulation in WT mice (3347±294 fmol cAMP/1x10
8
 platelets; p<0.05), but not CD36
-/-
 (4196±224fmol 
cAMP/1x10
8
 platelets) (Figure 3F). Furthermore, PGI
2
 induced phosphoVASP-ser
157
 (Figure 3G) and ser
239
 (Suppl. 
Figure 5) was reduced by oxLDL in WT, but not CD36
-/-
 platelets.  
 
Atherogenic lipid stress induces platelet PDE3A activity through a mechanism that requires CD36, Src 
kinases and PKC. 
Our data suggested that ligation of CD36 could activate PDE3A. We tested this directly measuring enzymatic 
activity of PDE3A immunoprecipitated from platelets treated with either oxLDL or oxPC
CD36
. PDE activity in the 
immunoprecipitated samples was blocked by milrinone confirming enzyme activity was due to PDE3A (Suppl. 
Figure 6). OxLDL (10-100 µg/ml) caused a concentration-dependent increase in PDE3A activity (Figure 4Ai), 
which plateaued at 50 µg/ml (24±6.8%; p<0.05 compared to basal) and was maintained at 27.7%±8.5 above 
basal for up to 60 minutes (longest time tested) (Figure 4Aii). This was strikingly different from the 
physiological agonist thrombin which induced a rapid induction of PDE3A activity that peaked at 1 minute 
before returning to basal after 5 minutes (Suppl. Figure 7).  
To link the sustained activation of PDE3A to decreased cAMP levels, we assessed the cyclic nucleotide 
concentrations over time. Platelets were incubated with oxLDL for up to 60 minutes, followed by a 1 minute 
treatment with PGI
2 
(50nM) before measuring cAMP concentrations. The pre-incubation of platelets with 
oxLDL, but not nLDL (data not shown), for up to 60 minutes significantly blunted PGI
2 
induced increases in 
cAMP with concentrations remaining at basal levels for the time course (Figure 4B). To confirm the role of CD36 
in the activation of PDE3A, experiments were repeated with oxPC
CD36
. In human platelets, oxPC
CD36
 (25 µM), 
but not PAPC (25 µM), increased PDE3A activity (26.9±7.3%; p<0.05 compared to basal and PAPC) (Figure 4C). 
Critically, oxPC
CD36
 stimulated activity in WT platelets to 25.4±2.4% (p<0.05 compared to basal or PAPC), but 
not in CD36
-/-
 platelets (Figure 4D).  
We previously described a CD36-specific signalling pathway that includes the sequential activation of Src-family 
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kinases (SFK), Syk, PLCγ2 and protein kinase C (PKC)17 and investigated whether these kinases were involved in 
the activation of PDE3A. The non-selective SFK inhibitor, Dasatinib (10 µM), ablated oxPC
CD36
-induced PDE3A 
activation (Figure 4E), while the Syk inhibitor, R406 (1 µM), caused significantly reduced PDE3A activity (Figure 
4F). Given that CD36 signalling leads to PKC activation in a SFK manner and that PDE3A is a target of PKC in 
platelets
31
, we tested the PKC inhibitors RO318220 (10 µM) and BIM1 (10 µM), and the intracellular Ca
2+
 chelator 
BAPTA-AM (20 µM) (Figure 4G). These three inhibitors blocked PDE3A activity induced by oxLDL, suggesting a 
PKC-dependent pathway (p<0.05). Platelet PDE3A activation is associated with phosphorylation of key serine 
residues
31
. We examined two of the most characterised sites, ser
312
 (PKA and PKC sensitive) and ser
428
 (PKC 
sensitive). OxLDL led to a time-dependent phosphorylation of ser
428
 which peaked at 2 minutes and was still 
evident at 10 minutes, but had no effect on phosphoPDE3Aser
312
. In comparison thrombin (0.1 U/ml) induced 
significantly less phosphorylation at ser
428
, which peaked at 1 min before returning to basal at 2 minutes (Figure 
4H), but also induced phosphorylation of ser
312
. These data confirm that oxLDL and its associated oxidised 
phospholipids require the sequential ligation and activation of CD36, Src, Syk and PKC to activate PDE3A.   
 
Dyslipidaemia is associated with platelet PGI
2
 hyposensitivity in mice.  
To demonstrate the functional importance of our observations on dyslipidaemia driven thrombosis, we 
examined platelet sensitivity to PGI
2
 in mice fed a Western diet (45%). cAMP signaling, integrin α
IIb
β3 activation 
and thrombosis were assessed in whole blood ex vivo, this allowed us to evaluate platelet function and 
thrombotic potential while avoiding any confounding effects of altered PGI
2 
synthesis in vivo associated with 
dyslipidaemia
32
.  Western diet significantly raised cholesterol levels (Suppl. Figure 8) and the presence of 
oxidised phospholipids in the plasma (Figure 5A). We then investigated the effect of dyslipidaemia on cAMP 
signaling using multiplexed phosphoflow cytometry to allow the examination of signaling under the 
physiological conditions of whole blood
24
. Platelets from high-fat fed WT animals produced significantly less 
phosphoVASP-ser
157
 when challenged with PGI
2
 (100 nM) than normal chow WT mice(4.9±0.4 fold versus 
6.2±0.2 fold increase over basal; p<0.05) (Figure 5B). The deletion of CD36 protected cAMP signaling in 
dyslipidaemic blood with phosphoVASP-ser
157
 remaining at control levels (Figure 5B). In parallel experiments, 
blood was stimulated with CRP-XL (10 µg/ml), in the presence and absence of PGI
2 
(100 nM), and α
IIb
β
3
 
activation measured. In normal chow WT blood, PGI
2
 caused 75.7±3.9% inhibition of integrin activation (p<0.05 
compared to absence of PGI
2
), which was blunted in high-fat fed WT blood (43.1%±7.6 inhibition, p<0.05, 
compared to normal chow) Figure 5Ci). Conversely, in CD36
-/- 
blood, PGI
2
 induced inhibition of integrin 
activation was not significantly different in normal chow and high-fat fed conditions (66.5±8% and 79.3±6.5% 
respectively) (Figure 5Ci and Cii).  
When we assessed ex vivo thrombosis under flow normal chow WT blood formed small thrombi on immobilised 
collagen in a time dependent manner, which was abolished by PGI
2
 (20 nM) (Figure 5Di). High-fat fed WT blood 
showed an accelerated thrombotic response with increased surface area (11±3.6% compared to 16.2±4.3% at 2 
mins). In addition, dyslipidaemia induced significant hyposensitivity to PGI
2
, with the prostanoid causing 
31.7±10.7% inhibition compared 61.6±5.6% with normal chow (p<0.05; 2 minutes) (Figure 5ii and iii). In contrast, 
the accelerated platelet deposition on collagen and platelet hyposensitivity to PGI
2
 was not detected in CD36
-/-
 
high-fat fed blood (Figure 5D). We repeated the experiments with 8-CPT-6-Phe-cAMP, as if PDE3A activation 
was responsible for the increased thrombotic potential associated with reduced sensitivity to PGI
2
, then CPT-6-
Phe-cAMP mediated inhibition of thrombosis would be unaffected by dyslipidaemia. The cAMP analogue 
caused a similar degree of inhibition of thrombosis in all genotypes, but critically, remained unaffected in the 
context of dyslipidaemia (WT-normal chow, 65.6±11.2%; WT-Western diet, 62.3± 7.7%; CD36
-/-
-normal chow, 
70.4±2.0%; CD36
-/-
-Western diet, 62.3±5% inhibition) (Suppl. figure 9). Here we show a physiological role for 
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platelet CD36 in dyslipidaemia, where it drives a phenotype of platelet hyperactivity through the blockade of 
cAMP mediated inhibition. 
 
OxLDL potentiation of thrombosis in vivo is prevented by inhibition of PDE3A. 
To examine the role of oxLDL in thrombosis in vivo we used intravital microscopy following ferric chloride–
induced carotid artery injury. Tail-vein injections of oxLDL (2.5mg/kg
-1
 bodyweight)
33,34
 into WT mice 
accelerated post-injury thrombotic response at all time points compared to control PBS injection (Figures 6A-C; 
suppl. videos 1 and 2). Next animals were pretreated with milrinone to explore in principle whether PDE3A 
inhibition might diminish prothrombotic effects of oxLDL.  Consistent with previous studies, modulation of 
PDE3A activity reduced murine thrombosis (Figure 6A-C)
23
.  Importantly, the presence of milrinone (10 μmol/L) 
significantly reduced the ability of oxLDL to promote thrombosis at all time points post injury (p<0.05), (supple. 
video 3) suggesting the heightened thrombotic response in the presence of  oxLDL could be related, at least in 
part, to changes in PDE3A activity. 
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DISCUSSION 
The presence of oxidised lipid epitopes, including oxLDL, is thought to promote platelet hyperactivity in 
subjects with obesity, CAD and stroke
5,6,35
. It is established that oxidative modifications are a hallmark of 
dyslipidemia and these stimulate platelet activation directly through a number of distinct receptors
6,8,13
. 
Interestingly, platelets from patients with CAD and dyslipidemia show a reduced sensitivity to the inhibitory 
effects of PGI
2
. These observations coupled to pharmacological trials indicating that suppression of endothelial 
PGI
2 
synthesis increased rate of atherothrombotic events
36–39
 suggest that platelet sensitivity to PGI
2
 could play 
an undefined role in the development of  atherothrombotic events. Hence the aim of this study was to 
investigate whether oxLDL may promote unwanted platelet activation through the modulation of platelet 
sensitivity to PGI
2
. Using a combination of pharmacological and genetic approaches we show that oxidative 
lipid stress modulates platelet cAMP signaling leading to increased platelet activation.  Our key findings include 
(i) oxLDL and oxidised phospholipids decrease platelet sensitivity to PGI
2
, which is coupled to reduced platelet 
accumulation of cAMP and PKA mediated signaling, (ii) PGI
2
 hyposensitivity likely occurs via sustained 
activation of the cAMP hydrolysing enzyme PDE3A in response to oxLDL, (iii) the activation of PDE3A by oxLDL 
requires ligation of CD36, and (iv) that dyslipidaemia induces platelet hyposensitivity to PGI
2
 in a CD36-
dependent manner.   
In the first instance we used three increasingly physiological systems to show that exposure of platelets to 
oxLDL opposes the inhibitory effects of PGI
2
. In contrast, oxLDL failed to affect platelet inhibition by 8-CPT-6-
Phe-cAMP, a PDE-resistant cAMP analogue, demonstrating firstly that the PKA signalling was intact, and 
secondly, that the effects of the oxidised lipoprotein may regulate cAMP availability.  Exploration of the 
underlying mechanisms demonstrated that OxLDL prevented the accumulation of cAMP in response to both 
PGI
2
 and forskolin.  Forskolin increases cAMP in a receptor-independent manner, thereby provides evidence 
that oxLDL did not affect the interaction of PGI
2
 with the IP receptor or target adenylyl cyclases. This is 
consistent with previous studies demonstrating that reduced platelet sensitivity to PGI
2 
in patients with 
hypercholesterolaemia was independent of any changes in cAMP synthesis by adenylyl cyclase
36
.  It was 
therefore possible that oxLDL could either prevent the synthesis of cAMP or accelerate its break down. We 
further found that oxLDL failed to modulate cAMP concentrations in the presence of the PDE3 inhibitor 
milrinone, but not the PDE2 inhibitor EHNA, suggesting that cAMP hydrolysis by PDE3A was the potential 
mediator of PGI
2 
hyposensitivity. A role for PDE3A was confirmed using immunoprecipitation experiments 
showing that both oxLDL and oxPC
CD36
 accelerated the hydrolytic activity of PDE3A in both human and murine 
platelets through ligation of CD36. The activation of PDE3A downstream of CD36 required the activation of Src 
family kinases, Syk and PKC. This provides further evidence that CD36-SFK-Syk represents a multiprotein 
complex that transduces extracellular oxidative lipid stress to the intracellular signalling machinery of the 
platelet. Interestingly, haemostatic agonists such as thrombin and collagen also activate PDE3A through a PKC-
dependent mechanism
31
. These agonists are proposed to cause a rapid attenuation of cAMP signalling at sites 
of vascular injury to promote platelet-mediated haemostasis. However, in contrast to the rapid and short-lived 
activation of PDE3A activity by thrombin and collagen, oxLDL induced a sustained PDE3A response for up to 60 
minutes (longest time tested). This was linked to a different activatory phosphorylation pattern of PDE3A by 
oxLDL and could suggest a distinct mechanism of activation induced by short-lived haemostatic agonists from 
that of oxLDL. Given the sustained activation of platelet PDE3A in the presence of oxidative lipid stress, it is 
attractive to speculate that PDE3A may be partially activated in dyslipidaemic disease states and thereby 
reduce the threshold for platelet activation by diminution of cAMP. Indeed, gain of function mutations of PDE3 
are associated with stroke, underlining its role in vascular pathology
40
. This concept is also supported by the 
observations that inhibtion of PDE3A by cilostazol can have beneficial anti-thrombotic effects in high risk 
groups characterised by a prothrombotic phenotype 
41–43
.  
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The pathophysiological consequences of platelet hyposensitivity to PGI
2
 and the potential importance of CD36 
was explored in a murine model of high-fat feeding induced dyslipidaemia. Interestingly, we found that even 
mild dyslipidaemia was characterised by the presence of oxidised lipid epitopes in the plasma, which was 
unaffected by the absence of CD36. Whole blood phospho-flow cytometry was used to measure platelet 
phosphoVASP, as a marker of cAMP signalling, without the need for cell isolation. This demonstrated that mild 
dyslipidaemia was accompanied by reduced cAMP signalling. The functional importance of this blunted cAMP 
signalling response manifested as diminished platelet sensitivity to the inhibitory effects of PGI
2
 on integrin 
activation measured by flow cytometry and ex vivo thrombosis. The assessment of thrombosis ex vivo was 
important to demonstrate that hyposensitivity of platelets to PGI
2
 was a primary platelet defect rather than a 
response to a dysfunctional endothelium, where altered PGI
2
 production has been observed in models of 
dyslipidaemia
32
. To support our hypothesis that hyposensitivity to PGI
2
 was linked to PDE3A activity, we 
showed that cAMP signalling in dyslipidaemia was normal if a PDE-resistant cAMP (8-CPT-6-Phe-cAMP) was 
used, again confirming that PKA signalling downstream of cAMP was functional. Critically, genetic ablation of 
CD36, protected animals from the loss of PGI
2 
sensitivity
 
and restored
 
PKA signalling.  Infusions of oxLDL into 
wild type mice caused a robust potentiation of thrombosis induced by ferric chloride. However, mice were 
protected from the prothrombotic effects of oxLDL in vivo when PDE3A was pharmacologically inhibited.  
Using this approach milrinone did not target only platelets and could therefore have effects on other PDE3A 
expressing cells. However, the data are proof of principle that the pro-thrombotic effects of oxLDL in vivo, at 
least in part, may be prevented by therapeutic strategies based on enhancing or preserving cAMP signalling 
events in platelets. This element of the work requires further studies focussing on strategies for the specific 
targeting of PDE3A, and potentially PDE2, in platelets.  
Together, our ex vivo and in vitro data suggests a previously unrecognised mechanism contributing to platelet 
hyperactivity, whereby the ligation of CD36 by oxidised lipids modulates cAMP signalling through 
activation of PDE3A activation leading to PGI
2
 hyposensitivity. This data may constitute a link to the observed 
PGI
2 
hyposensitivity in dyslipidaemic high-risk populations and indicate a novel therapeutic strategy to target 
atherothrombotic risk in certain patient groups. Remarkably, current antiplatelet therapy exclusively targets 
platelet activatory pathways including cyclooxygenases (Aspirin), P2Y12 (Thienopyridines, non-
Thienopyridines) or α
IIb
β
3
 (Tirofiban; Eptifibatide) while platelet inhibitory pathways remain untargeted. 
Therefore, high-risk populations might remain at increased atherothrombotic risk despite optimal available 
pharmacological therapy and impaired platelet inhibition might contribute to the residual cardiovascular risk.  
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Figure 1: OxLDL induces PGI
2 
hyposensitivity in platelets. 
(A) Washed human platelets (2.5 x 10
8
/ml) were treated alone or with nLDL or oxLDL (50µg/ml) for 2 minutes 
followed by a 1 minute incubation with PGI
2 
(20nM). Thrombin(0.05U/ml)-stimulated aggregation was then 
measured under constant stirring (1000 rpm) at 37°C for 4 minutes. In some cases, platelets were incubated with 
either thrombin, nLDL or oxLDL alone for 4minutes. (i) Representative aggregation traces. (ii) Percentage 
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aggregation is presented by mean ± SEM (n= 5, **p< 0.01 compared to platelets treated with thrombin and PGI
2
, 
Mann-Whitney U Test). (B) Whole blood was treated as in (A) and activated with PAR-1 peptide (10µM) for 5 minutes 
followed by fixation. P-selectin expression was assessed by flow cytometry. Representative data of 3 independent 
experiments. (i) Data is presented as heatmap of fold-change MFI. (ii) representative histograms. (C) Human whole 
blood was incubated with PGI
2 
(20nM) for 1 minute alone or with nLDL or oxLDL (50µg/ml) for 10 minutes. Blood was 
perfused over collagen-coated biochips for 2 minutes at arterial shear 1000s
-1
 and images of adherent platelets were 
taken by fluorescence microscopy. (i) The surface coverage (%) is presented as mean±SEM (n=3)(p<0.05, Mann-
Whitney U Test). (ii) Representative fluorescence microscopy images are shown. (D) Whole blood was incubated with 
nLDL or oxLDL (50µg/ml) for 10 minutes and then perfused over collagen-coated surfaces for 2 minutes at arterial 
shear 1000s
-1
. Thrombi were post-stained with anti-oxPC antibody and images were taken by fluorescence 
microscopy. (i) Representative of images of 3 independent experiments. Stained with DIOC
6
 (top panel) or anti-oxPC 
(bottom panel) (ii) The surface coverage is presented as mean ± SEM (n=4, *p< 0.05, Mann-Whitney U Test). (iii) 
Fluorescence (red Channel) is presented as mean ± SEM (n=4, *p< 0.05, Mann-Whitney U Test). 
 
Figure 2: OxLDL modulates cAMP signalling in response to PGI
2
. 
(A) Washed human platelets (2x10
8
/ml) incubated with apyrase, indomethacin and EGTA were treated alone or with 
nLDL or oxLDL (50µg/ml) for 2 minutes followed by a 1 minute PGI
2 
(50nM) incubation. Platelets were lysed and 
intracellular cAMP concentrations were measured by enzyme immunoassay. (i) Intracellular cAMP levels presented 
as mean ± SEM (N=3, *p<0.05, Mann-Whitney U Test). (ii) Platelets treated as described under (A) in the presence 
EHNA (20µM). Intracellular cAMP levels presented as mean ± SEM (N=3, *p<0.05, Mann-Whitney U Test) (iii) 
Platelets treated as described under (A) in the presence of Milrinone (10µM). Intracellular cAMP levels presented as 
mean ± SEM (N=3, *p<0.05, Mann-Whitney U Test). (B) Washed human platelets (2x10
8
/ml) incubated alone or with 
oxLDL (50µg/ml) for 2 minutes followed by a 5 minute incubation with Forskolin
 
(10µM). Lysed and measured as 
described under (A). Intracellular cAMP concentrations presented as mean ± SEM (N=3, *p< 0.05, Mann-Whitney U 
Test). (C) Washed human platelets (5x10
8
/ml) treated as described under (A), lysed in Laemmli buffer, separated by 
SDS-PAGE and immunoblotted with anti-phosphoPKA substrate, anti-phosphoVASPser
157
 and anti-β tubulin. (i) 
Representative blot of 3 independent experiments. (ii) Densitometry of the representative highlighted band (red) 
(*p<0.05, Mann-Whitney U Test) (D) Washed human platelets were treated as described under A except, platelets 
were treated with
 
8-CPT-cAMP (50µM) for 5 minutes and then processed as in (C). (i) Representative blot of three 
independent experiments and (ii) Densitometry of the representative highlighted band (red).  
 
Figure 3: OxLDL and oxPC
CD36 
alter PGI
2 
inhibitory signalling via CD36.  
(A) Washed human platelets (5x10
8
/ml) incubated with apyrase, indomethacin and EGTA were incubated with FA6-
152 or IgG (1µg/ml) for 20minutes. Platelets were then incubated alone or with nLDL or oxLDL (50µg/ml) for 2 
minutes and subsequently stimulated by PGI
2 
(50nM) for 1 minute.  Treated platelets were lysed in Laemmli buffer, 
separated by SDS-PAGE and immunoblotted with anti-phosphoVASPser
157
 or anti-β tubulin. (i) Representative blot 
of 3 independent experiments. (ii) Densitometry of pVASPser
157
 fold-change above basal mean ± SEM (n=3 *p<0.05, 
Mann-Whitney U Test). (B) as in (A) except platelets were probed for phosphoVASPser
239
. (C) Platelets treated as in 
(A) alone or with oxPC
CD36 
or PAPC (25µM) for 2 minutes followed by PGI
2 
(50nM) for 1 minute. (i) Representative blot 
of 3 independent experiments and (ii) Densitometry of pVASPser
157
 fold-change above basal, mean ± SEM (n=3 
*p<0.05, Mann-Whitney U Test). (D) Washed wild-type murine platelets (2.5x10
8
/ml) were treated alone or with 
oxPC
CD36
 or PAPC (10µM) for 2 minutes followed by a 1 minute incubation with PGI
2 
(20nM). Thrombin(0.05U/ml)-
stimulated aggregation was then measured under constant stirring (1000 rpm) at 37°C for 4 minutes. (i) 
Representative aggregation traces and (ii) data presented as percentage aggregation, mean ± SEM (n=3, p<0.05, 
Mann-Whitney U Test). (E) As described in (D) for CD36
-/-
 platelets. Ns= not significant. (F) Washed murine WT or 
CD36
-/-
 platelets (2x10
8
/ml) were treated alone or with nLDL or oxLDL (50µg/ml) for 2 minutes followed by a 1 minute 
PGI
2 
(50nM) incubation. Platelets were lysed and intracellular cAMP concentrations were measured by enzyme  
immunoassay. Intracellular cAMP levels presented as mean ± SEM (n=3, *p<0.05, Mann-Whitney U Test). (G) as in (A) 
except murine (i) WT and (ii) CD36
-/-
 platelets were used. Representative blot of 3 independent experiments. 
pVASPser
157
 is presented as beta-tubulin corrected fold-change above basal ± SEM (N=3 *p < 0.05, Mann-Whitney U 
Test). 
 
Figure 4: OxLDL and oxPC
CD36 
induce sustained PDE3A activity in a CD36-dependent manner. 
 (A) Washed human platelets (5x10
8
/ml) incubated with apyrase, indomethacin and EGTA were (i) incubated with 
nLDL (50µg/ml) or oxLDL (10-100µg/ml) for 2minutes or (ii) incubated with nLDL (50µg/ml) or oxLDL (50µg/ml) for up 
to 60 minutes. Platelets were lysed, PDE3A immunoprecipitated and enzyme activity was measured. Data is 
expressed as % activity above basal activity and presented as mean ± SEM (p <0.05; n=3, Kruskal-Wallis Test ). (B) 
Washed human platelets (5x10
8
/ml) were incubated with oxLDL (50µg/ml) for up to 60 minutes followed by PGI
2 
(50nM) for 1 minute. Platelets were lysed and intracellular cAMP levels were determined by enzyme immunoassay. 
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Data is presented as mean ± SEM (* p<0.05; n=3, Kruskal-Wallis Test). (C) Washed human platelets  (5x10
8
/ml
 
) were 
incubated with oxPC
CD36 
or PAPC (25µM) for 2 minutes and activity of immunoprecipitated PDE3A measured. Data is 
expressed as % activity above basal activity and presented as mean ± SEM (p <0.05; n=3 Mann-Whitney U Test).  (D) 
and in (C) except PDE3A activity was measured in WT and CD36
-/- 
washed
 
platelets (*p<0.05; n=3 Mann-Whitney U 
Test).  (E) as in (A) except human platelets (5x10
8
/ml) incubated with apyrase, indomethacin and EGTA were then 
treated with oxPC
CD36 
or PAPC (25µM) for 2 minutes in the presence of absence of Dasatinib (10µM) or vehicle control 
(DMSO). PDE3A was immunoprecipitated and enzyme activity measured. Data is expressed as % activity above basal 
activity and presented as mean ± SEM (p <0.05; n=4 Mann-Whitney U Test). (F) as in (A) except platelet were treated 
with R406 (1μM) or vehicle control (DMSO). (G) as in (A) except platelets were treated with PKC inhibitors (RO31 
10µM, BIM1 10µM), PMA (100nM), BAPTA (20µM) or vehicle control (DMSO). (n=3, * p < 0.05 compared to basal, 
Kruskal-Wallis Test ). (H) Washed human platelets (5x10
8
/ml) treated with apyrase, indomethacin and EGTA were 
incubated with or oxLDL (50µg/ml; 0-60minutes) or thrombin (0.1U/ml; 0-2minutes). Treated platelets were lysed in 
Laemmli buffer, separated by SDS-PAGE and immunoblotted with anti-phosphoPDE3Aser
312
, phosphoPDE3Aser
428 
or anti-β tubulin. (i) Representative blot of 3 independent experiments (ii) densitometry for phosphoPDE3Aser
428
 is 
presented as fold-change above basal, mean ± SEM (n=3, *p<0.05, Kruskal-Wallis Test). 
 
Figure 5: High-fat diet fed mice correlate increased plasma levels of oxidised phospholipids to reduced PGI
2 
sensitivity via CD36.  
(A) Representative dot blots of mouse plasma probed with anti-oxidised phospholipids (HRP-conjugated-E06) and 
total-IgG (HRP-conjugated anti-mouse). (B) Whole blood from normal chow and High-fat fed animals were treated 
with PGI
2 
(100nM) for 1 minute.
 
Blood was fixed, permeabilised and incubated with anti-pVASPser
157
 followed by 
secondary fluorescent-conjugate (Alexa 647) and analysed by flow-cytometry. (i) Representative heat map of fold 
increase in phosphoVASPser
157
. Quantification is presented as fold-change of median fluorescence intensity above 
basal (n=4, *p<0.05, Mann-Whitney U Test). (C) Whole blood from normal chow and high-fat diet fed animals were 
treated with PGI
2 
(100nM)
 
for 1 minute followed by CRP (10µg/ml) for 5 minutes. Blood was fixed and JON/A positive 
cells were analysed by flow-cytometry. (i) Representative histograms. (ii) Data presented as percentage inhibition of 
JON/A binding, mean ± SEM (n=4 * p<0.05, Mann-Whitney U Test). (D) Whole blood incubated alone or with PGI
2 
(20nM) for 1 minute was perfused at arterial shear 1000s
-1
 for 2 minutes over a collagen matrix (50µg/ml). Images of 
adherent platelets were taken by fluorescence microscopy. (i) surface coverage (%) presented as a function of time 
(ii) Representative images of arterial flow experiments, (iii) Data presented as inhibition of surface coverage (%), 
mean ± SEM
 
(n=5; * p<0.05, Mann-Whitney U Test). 
 
 
Figure 6: OxLDL induced thrombosis in vivo is prevent by inhibition of PDE3A. 
Intravital microscopy was performed as described in “supplementary methods.” (A) Representative fluorescence 
images of thrombi formed under different conditions are shown over the course of 40minutes after vascular injury. 
Black arrow shows the direction of blood flow. (B) Representative median integrated fluorescence signals of 
Rhodamine G obtained from an individual carotid thrombus under different conditions. (C) Quantified median 
integrated fluorescence signals from 10, 20, 30 and 40 minutes after vascular injury taken from 5 WT for each 
treatment. *p< 0.05; **p< 0.01, Kruskal-Wallis Test. 
 
Figure 7: Proposed signalling pathway downstream of CD36 through which oxLDL activates PDE3A to suppress 
cAMP signalling. 
OxLDL binds to CD36 to activate a tyrosine kinase signalling pathway that leads to a sustained activation of PDE3A.  
Under these conditions cAMP is maintained at low concentrations through hydrolysis to 5’AMP (solid red line) and 
the activation of PKA is diminished (dashed red line). Through disinhibition this pathway acts to reduce the threshold 
for platelet activation and promote thrombosis.  
 
 
 







SUPPLEMENTARY METHODS. 
 
Platelet preparation 
Human washed platelets (WP) were isolated from blood taken from drug-free volunteers as previously 
described. 1 All Human work was approved by the Hull York Medical School Ethics Committee. Human 
blood was taken from drug-free volunteers by clean venepuncture using acid citrate dextrose (ACD; 
29.9mM sodium citrate, 113.8mM glucose, 72.6mM sodium chloride and 2.9mM citric acid, pH 6.4) as 
anticoagulant. Platelet-rich plasma (PRP) was obtained by centrifugation of whole blood at 200g at 20°C 
for 20minutes. PRP was treated with citric acid (0.3M) and centrifuged at 800g for 12 minutes. The platelet 
pellet was then suspended in wash buffer (36mM citric acid, 10mM EDTA, 5mM glucose, 5mM KCl, 9mM 
NaCl) and spun once more at 800g for 12 minutes. Platelets were finally re-suspended at the indicated 
concentration in modified Tyrodes buffer (150mM NaCl, 5mM HEPES, 0.55mM NaH2PO4, 7mM NaHCO3, 
2.7mM KCl, 0.5mM MgCl2, 5.6mM glucose, pH7.4). 
Murine blood obtained by cardiac puncture was taken into PPACK by under terminal CO2 narcosis. PRP 
was obtained by centrifugation of whole blood at 300g for 10min at room temperature. The PRP was then 
centrifuged at 1000g after addition of citric acid (0.3M) for 6minutes at room temperature. The pellet was 
resuspended in modified Tyrodes buffer, spun again at 1000g for 6minutes and then finally resuspended 
at the indicated concentration in modified Tyrodes buffer. When required for signalling experiments, 
platelets were incubated with ethylene-glycol-bis-tetraacetic acid (EGTA; 1mM), indomethacin (10µM) 
and apyrase (2U/ml) for 15 minutes before experimentation.   
 
Platelet aggregation 
WP (2.5×108 platelets/mL) were incubated with oxLDL/LDL (50µg/ml) at 37oC for 2 minutes followed PGI2 
(20nM) for 1 minute and then the addition of thrombin (0.05U/mL) or collagen (5µg/ml) and aggregation 
monitored under constant stirring for 4 minutes using a Chronolog Dual Channel Platelet Aggregometer. 
 
Platelet flow assays 
For the in vitro thrombosis assay human whole blood was incubated with DiOC6 (1µM) and treated with 
oxLDL/LDL (50µg/mL) in the presence and absence of PGI2 (20nM). Assays were performed using Vena8 
biochips (Cellix; Dublin, Ireland), coated with collagen (50µg/ml) for 12 hours, and blocked with BSA 
(10mg/mL) for 1hour. For ex vivo experiments murine blood was treated in the same manner except the 
addition of nLDL/oxLDL was omitted. Flow was performed for 2minutes at 1000s-1. Images of stably 
adhered platelets and thrombi were captured using fluorescence microscopy and analysed using ImageJ 
software. Data are presented as surface area coverage (%), since the software could not fully 
discriminate between single platelets and platelet aggregates. 2  
 
Flow cytometric analysis  
Flow cytometry assays were performed with whole blood from either mice or human subjects. For human 
studies, whole blood was incubated with oxLDL/LDL (50µg/ml) at 37oC for 2 minutes, followed by PGI2 
(20nM) for 1 minute and the assay initiated by the addition of PAR-1 peptide (10µM).  Flow cytometry 
was performed using a BD LSRFortessa and analysed for P-selectin expression. For murine studies 
blood was harvested and examined for phosphoVASP or JonA binding. For PhosphoVASP a 
phosphoflow cytometry approach was used. In brief, whole blood was incubated with PGI2 (20nM) for 1 
minute. Cells were then pelleted by centrifugation at 1000g at 4°C, for 10min, the supernatants removed 
and the remaining platelets permeabilised for 10 min with 0.1% Triton X-100 in phosphate buffered saline 
(PBS). Permeabilised platelets were pelleted (1000g at 4°C, for 10minutes) washed with PBS and 
incubated with phosphospecific antibodies (2µg/mL) on ice for 30 minutes. Platelets were washed with 
PBS and incubated with a secondary antibody labeled with AlexaFluor 647 (1µg/mL) on ice in the dark 
for 45 minutes. After washing with PBS, platelets were transferred to FACS tubes for flow cytometric 
analyses using a BD LSRFortessa. 3 For JON/A binding platelet were incubated with PGI2 (100nM) for 1 
minute followed by addition of CRP-XL (10µg/ml) for 5minutes. After fixation platelets were stained and 
processed using a BD LSRFortessa 
 
Immunoblotting 
Washed platelets (5×108 platelets/mL), incubated with apyrase (2U/mL), indomethacin (10µmol/L) and 
EGTA (1mmol/L), were treated with oxLDL/nLDL (50µg/ml for 15min) prior to the addition of PGI2 (20nM) 
for 1 minute at 37°C before termination with Laemmli buffer. In some cases, platelets were incubated 
with the CD36 blocking antibody FA6-152 or IgG (1µg/mL), for 20min at 37°C prior to addition of oxLDL. 
Whole cell lysates were separated by SDS-PAGE and transferred to PVDF membranes.  Membranes 
were blocked for 60minutes with 10% BSA or 5% milk dissolved in Tris-buffered-saline-Tween (0.1%) 
(TBS-T) then incubated with anti-phosphoPKA substrate (1:1000), anti-phosphoVASP-ser239 (1:1000), 
anti-phosphoVASP-ser157 (1:1000), anti-pDE3Aser428 (1:250), anti-pDE3Aser312 (1:250) or an anti b-
tubulin antibody (1:1000). Membranes were developed with enhanced chemiluminescence (ECL) 
solutions.  
 
cAMP measurement 
Intracellular cAMP concentrations were quantified using an enzyme immunoassay (EIA) (GE Healthcare). 
cAMP is measured through the competition between cAMP in a test sample and a fixed quantity of 
peroxidase-labeled cAMP, for a limited number of binding sites on a cAMP specific antibody.  WPs 
(2x108/ml) were treated with the indicated agents for selected time intervals and lysed with 10x lysis 
buffer 1A (2.5% dodecyltrimethylammonium in assay buffer). An aliquot (100μl) of each sample was 
added to a 96 well plate in triplicate. After a 2 hour incubation at 4°C with gentle shaking, cAMP-
peroxidase conjugate (50μl) was then added to each well and incubated for 1 hour at 4°C with gentle 
shaking. Following incubation, the wells were then washed four times and hydrogen peroxide substrate 
was added to each well. Absorbance was read at 630nm using a TECAN infinite M200 microplate reader.  
 
Measurement of PDE3A activity 
To measure intracellular PDE activity we used a commercially available non-radioactive colorimetric 
assay. WPs (5x108/ml) were treated as described, lysed in 2x PDE extraction buffer (150mM NaCl, 50mM 
HEPES, 20% glycerol (v/v), 10% Igepal (v/v), 1mM, EDTA, 1:200 phosphatase inhibitor cocktail (v/v), 
protease inhibitor cocktail 1:100 (v/v)) and immediately placed on ice. PDE3A was immunoprecipitated 
from 500μg of protein lysate using 1μg of anti-PDE3A antibody or matched IgG control. 
Immunoprecipitates were incubated with 5’-nucleotidase and of cAMP (0.5mM) substrate at 37°C for 1 
hour and the production of 5’-AMP measured following the manufacturers instructions.  Activity was 
expressed as fmol AMP/min 1x107 platelets and normalised to control values to account for variations 
in basal activity between individual platelet donors. 
 
Intravital imaging of in vivo thrombosis 
Left carotid artery of anaesthetised mice was exposed and mice injected with Rhodamine G followed 
by either oxLDL (2.5mg/kg-1 body weight) or an equal volume of PBS through the tail vein. 4,5 In some 
mice, milrinone (10μmol/L) was injected 5 minutes prior to oxLDL injection. 10 minutes after the injection 
of oxLDL, injury was induced by applying 1x2mm filter paper saturated with anhydrous FeCl3 (10%). 
Filter paper was placed on the right adventitial surface of the vessel for 1minute then removed. 
Thrombosis was recorded using high-speed intravital microscopy for up to 40 minutes. The integrated 
intensity value (Median Fluorescence Intensity) of the thrombus was measured over time and time taken 
to reach peak was determined. Five individual mice were used for each condition. 
 
Statistics.  
Results are expressed as means ± SEM and statistical analyses were undertaken using Prism 6.0 
(GraphPad, La Jolla, California). Comparisons between groups were performed by an unpaired, Mann-
Whitney U test. P values of less than 0.05 were considered statistically significant. 
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Supplementary Figure 1: OxLDL induces PGI2 hyposensitivity in platelets. 
Washed human platelets (2.5 x 108/ml ) were incubated with nLDL or oxLDL (50µg/ml) for 2 minutes followed 
by PGI2 (20nM) for 1 minute. Collagen-stimulated aggregation was then measured under constant stirring 
(1000 rpm) at 37°C for 4 minutes. (i) Representative aggregation traces (ii) Data is expressed as percentage 
aggregation and presented as mean ± SEM (n= 5, * p< 0.05 compared to PGI2 alone).  
 
Supplementary Figure 2: 8-CPT-6-Phe-cAMP is resistant to PDE3a. 
PDE3A immunoprecipitates were incubated with cAMP and 8-CPT-6-Phe-cAMP and enzyme activity was 
measured by production of 5’AMP after 1hour at 37°C. N=2  
 
Supplementary Figure 3: 8-CPT-6-Phe-cAMP increases intracellular cAMP. 
Platelets were incubated with PGI2 (50nM) or 8-CPT-6-Phe-cAMP (50µM) for 5 minutes. Platelets were 
washed, lysed and intracellular cAMP levels were determined by enzyme immunoassay. Data is presented 
as mean ± SEM.  
 
 
Supplementary Figure 4: Immunoblotting of platelet lysates for CD36 
Washed human platelets, WT murine platelets and CD36-/- platelets (5x108/ml) were lysed with Laemmli 
buffer, separated by SDS-PAGE and immunoblotted with anti-CD36. Representative blot of 3 independent 
experiments  
 
Supplementary Figure 5: OxLDL modulation of VASP239 phosphorylation in murine platelets 
Washed murine WT or CD36-/- platelets (5x108/ml) were treated alone or with nLDL or oxLDL (50µg/ml) for 2 
minutes followed by a 1 minute PGI2 (50nM) incubation. Treated platelets were lysed with Laemmli buffer, 
separated by SDS-PAGE and immunoblotted with anti-phosphoVASPser239 or anti-β tubulin. Representative 
blot of 3 independent experiments. 
 
Supplementary Figure 6: Immuniprecipitated phosphodiesterase is sensitive to milrinone. 
Washed human platelets (2.5x108/ml) lysed and PDE3A was immunoprecipitated. Enzyme activity measured 
by cAMP hydrolysis for 1hour at 37°C in the presence and absence of Milrinone (20µM). Data is presented 
as % activity with basal representing 100%  (n=3). 
 
Supplementary Figure 7: Thrombin induced activation of PDE3A as a function of time. 
Washed human platelets (2.5x108/ml) stimulated with thrombin (0.1U/ml) for up to 60 minutes before lysis. 
PDE3A was immunoprecipitated and enzyme activity measured by cAMP hydrolysis for 1hour at 37°C. Data 
is presented as % over basal activity (n=3).  
 
Supplementary figure 8: Plasma cholesterol concentrations from WT and CD36-/- mice. 
WT and CD36-/- mice were fed either normal chow or High fat diet. Plasma was isolated from whole blood 
and the concentration of cholesterol measured. Data is expressed as mg/dl cholesterol and presented as 
mean ± SEM (n=5). * p<0.05). 
 
Supplementary figure 9: High-fat diet fed animals show normal platelet sensitivity to PDE-resistant 
cAMP analogue. 
Whole blood of normal chow and high-fat diet fed animals treated with 8-CPT-6-Phe-cAMP (50µM) for 5 
minutes was perfused at arterial shear 1000s-1 for 2 minutes over a collagen (50µg/ml). Images of adherent 
platelets were taken by fluorescence microscopy. (i) Representative images of arterial flow experiments, (ii) 
Data expressed as percentage inhibition of surface coverage, mean ± SEM  (n=5; ns = not significant). 
